Abstract: A method of non-invasively monitoring hemoglobin concentration includes providing incident light to patient tissue at a first excitation wavelength. The method further includes monitoring a first emission response at a first emission wavelength, wherein the first emission wavelength is selected to correspond with a maximum of the emission response, and monitoring a second emission response at a second emission wavelength, wherein the second emission wavelength is selected to correspond with a minimum of the emission response. A hemoglobin concentration is calculated based on a ratio of the first emission response to the second emission response.

Abstract: A medical device is utilized to monitor physiological parameters of a patient and capture segments of the monitored physiological parameters. The medical device includes circuitry configured to monitor one or more physiological parameters associated with the patient and an analysis module that includes a buffer and a processor. The buffer stores monitored physiological parameters and the processor analyzes the monitored physiological parameters and triggers capture of segments from the buffer in response to a triggering criteria being satisfied. The analysis module selects a pre-trigger duration based at least in part on the triggering criteria.

Abstract: A medical device is utilized to monitor physiological parameters of a patient and capture segments of the monitored physiological parameters. The medical device includes circuitry configured to monitor one or more physiological parameters associated with the patient and an analysis module that includes a buffer and a processor. The buffer stores monitored physiological parameters and the processor analyzes the monitored physiological parameters and triggers capture of segments from the buffer in response to a triggering criteria being satisfied. The analysis module selects a pre-trigger duration based at least in part on the triggering criteria.

Abstract: Techniques are disclosed for detecting arrhythmia episodes for a patient. A medical device may receive one or more sensor values indicative of motion of a patient. The medical device may determine, based at least in part on the one or more sensor values, an activity level of the patient. The medical device may determine a heart rate threshold for triggering detection of an arrhythmia episode based at least in part on the activity level of the patient. The medical device may determine whether to trigger detection of the arrhythmia episode for the patient based at least in part on comparing a heart rate of the patient with the heart rate threshold. The medical device may, in response to triggering detection of the arrhythmia episode, collect information associated with the arrhythmia episode.

Abstract: A method of determining signal quality in a patient monitoring device includes acquiring one or more signals using the patient monitoring device. One or more signal quality metrics are determined based on the one or more acquired signals. A noise condition is detected based on the one or more signal quality metrics, and a determination is made whether the noise condition should be classified as intermittent or persistent. One or more actions are taken based on the classification of detected noise as intermittent or persistent.

Abstract: A method of non-invasively monitoring hematocrit levels includes monitoring a first emission response to the light provided at the first excitation wavelength, wherein the first emission response is monitored at a first wavelength and monitoring a second emission response to the light provided at the first excitation wavelength, wherein the second emission response is monitored at a second wavelength. A ratiometric value is calculated based on a ratio of the first emission response to the second emission response, wherein the ratiometric value corresponds with hematocrit level of the patient.

Abstract: A method of non-invasively monitoring advanced glycation end-product (AGE) concentrations includes providing incident light to patient tissue at one or more excitation wavelengths and monitoring the one or more emission responses at one or more emission wavelengths. Based on the emission responses monitored, a ratio is calculated based on a ratio of the first emission response to the second emission response.

Abstract: A method of non-invasively monitoring hemoglobin concentration includes providing incident light to patient tissue at a first excitation wavelength. The method further includes monitoring a first emission response at a first emission wavelength, wherein the first emission wavelength is selected to correspond with a maximum of the emission response, and monitoring a second emission response at a second emission wavelength, wherein the second emission wavelength is selected to correspond with a minimum of the emission response. A hemoglobin concentration is calculated based on a ratio of the first emission response to the second emission response.

Abstract: Embodiments relate to a method of monitoring physiological parameters of a patient with renal dysfunction. The method includes electrically connecting one or more medical device electrodes with a measurement site of a patient, generating one or more first stimulation signals sufficient to provide input physiological parameters specific to the patient, measuring one or more first bioimpedance values from the generated signals, analyzing at least one of the input physiological parameters within the one or more first bioimpedance values and generating a personalized dialysis program. The systems and methods can further provide essentially real-time data of patient undergoing treatment and control of treatment to a patient.

Abstract: Methods and apparatus to determine the presence of and track functional chronotropic incompetence (hereinafter “CI”) in an in-home setting under conditions of daily living. The functional CI of the patient may be determined with one or more of a profile of measured patient heart rates, a measured maximum patient heart rate, or a peak of the heart rate profile. The functional CI of the patient may be determined with the measured heart rate profile, in which the measured heart rate profile may correspond to heart rates substantially less than the maximum heart rate of the patient, such that the heart rate can be safely measured when the patient is remote from a health care provider. The functional CI of the patient may be determined based a peak of the remotely measured heart rate profile, for example a peak corresponding to the mode of the heart rate distribution profile.

Abstract: Described herein is a system and method of automatically monitoring QT intervals in a patient based on one or more EKG signals received from attached monitoring devices. Each EKG signal is analyzed to detect attributes of the first and second EKG signals, including QRS onset information, QRS peak information, and T-wave offset information. A QT interval is calculated based on QRS onset information derived from the first EKG signal and T-wave offset information derived from the second EKG signal. The calculated QT interval is compared to thresholds to detect elongation of the QT interval and an alert is generated in response to a detected elongated QT interval.

Abstract: Systems, devices and methods transmit data from a patient device to a location, for example a remote location, where the patient is monitored. The system may comprise a server system, for example a backend server system, a gateway and the patient worn device. The gateway can be configured to communicate with the patient worn device in response to a list transmitted from the server, for example an approved patient device list transmitted from the server to the gateway. The gateway may exclude communication with patient worn devices that are not on the list. This use of the list can control data throughput from the patient device to the gateway and also from the gateway to the server, such that the communication from the device on the list to the server is maintained and appropriate information can be reliably sent from the patient device to the server.

Abstract: A patient monitoring device includes reusable and disposable portions. The disposable portion includes two or more electrodes for coupling to the skin of the patient, a battery, and a first set of electrical contacts. The reusable portion includes a processor, memory, a second set of electrical contacts, and sensing circuitry coupled to the at least two electrodes, wherein the reusable portion is mechanically coupleable to the disposable portion and wherein the reusable portion is electrically coupleable to the disposable portion through the first and second electrical contacts. The sensing circuitry and the processor are powered from the battery through the coupled first and second electrical contacts, and wherein when the reusable portion and the disposable portion are mechanically uncoupled after having been mechanically coupled, the disposable portion is rendered unusable by the process of mechanically uncoupling the reusable portion and the disposable portion.

Abstract: Embodiments of the present disclosure describe a method of monitoring a patient comprising generating an accelerometer signal of a patient via a patient medical device and capturing and sampling the accelerometer signal at a sampling rate that utilizes non-regular timing intervals. Embodiments further describe a patient medical device comprising sensors for monitoring an accelerometer signal of a patient and circuitry for sampling the accelerometer signal at a sampling rate that utilizes non-regular timing intervals. Embodiments also describe a method of processing physiological signals comprising monitoring ECG signals and accelerometer signals of a patient via a patient medical device and capturing an ECG segment and sampling the accelerometer signal at a sampling rate that utilizes non-regular timing intervals.

Abstract: An injectable detecting device is provided for use in physiological monitoring. The device includes a plurality of sensors axially spaced along a body that provide an indication of at least one physiological event of a patient, a monitoring unit within the body coupled to the plurality of sensors configured to receive data from the plurality of sensors and create processed patient data, a power source within the body coupled to the monitoring unit, and a communication antenna external to the body coupled to the monitoring unit configured to transfer data to/from other devices.

Abstract: Embodiments describe a method of determining etiology of undiagnosed events comprising monitoring electrocardiogram signals and blood pressure of a patient via a medical device, capturing one or more of an ECG segment and a BP reading in response to a triggering event, classifying one or more of the ECG segment and BP reading as normal or abnormal, and determining etiology of undiagnosed symptomatic events based on the classification. Embodiments further describe a medical device comprising sensors for monitoring ECG signals and BP of a patient, circuitry for capturing one or more of ECG segments and BP readings of a patient in response to a triggering event, and a processor for communicating one of more of captured ECG segments and captured BP readings to a remote monitoring center directly or indirectly where the captured ECG segments and captured BP readings are classified as normal or abnormal.

Abstract: A method of non-invasively monitoring advanced glycation end-product (AGE) concentrations includes providing incident light to patient tissue at one or more excitation wavelengths and monitoring the one or more emission responses at one or more emission wavelengths. Based on the emission responses monitored, a ratio is calculated based on a ratio of the first emission response to the second emission response.

Abstract: A method of non-invasively monitoring hematocrit levels includes monitoring a first emission response to the light provided at the first excitation wavelength, wherein the first emission response is monitored at a first wavelength and monitoring a second emission response to the light provided at the first excitation wavelength, wherein the second zemission response is monitored at a second wavelength. A ratiometric value is calculated based on a ratio of the first emission response to the second emission response, wherein the ratiometric value corresponds with hematocrit level of the patient.

Abstract: A method of non-invasively monitoring hemoglobin concentration includes providing incident light to patient tissue at a first excitation wavelength. The method further includes monitoring a first emission response at a first emission wavelength, wherein the first emission wavelength is selected to correspond with a maximum of the emission response, and monitoring a second emission response at a second emission wavelength, wherein the second emission wavelength is selected to correspond with a minimum of the emission response. A hemoglobin concentration is calculated based on a ratio of the first emission response to the second emission response.

Abstract: A system and method of monitoring electrocardiogram (ECG) signals and detecting ischemic conditions. In particular, high-frequency components and low-frequency components are extracted from the monitored ECG signal. The high-frequency components are analyzed to detect reduced amplitude zones (RAZs), while the low-frequency components are utilized to detect premature ventricular contraction (PVC) beats. Potentially ischemic conditions are identified based on both RAZs and PVC beats detected.